Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro.  The company also recently announced a partnership with Walmart that will expand access to Zepbound ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

New Scripps Research trial will explore the effects of Lilly’s GLP-1 drug on reducing the symptoms of the debilitating ...

Shares of Danish rival Novo Nordisk slipped after it sought to snatch Pfizer target Metsera from the American drug giant's arms. Novo launched an unsolicited bid valued at up to $9 billion for obesity ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly.

Current health news highlights include Calley Means' departure from the White House, Cipla CEO Umang Vohra's upcoming resignation, a U.S. government shutdown threatening food aid, Eli Lilly's and Novo ...

The U.S. stock market sank from its record heights on Oct. 30, as Wall Street sifted through mixed developments on everything ...

Novo Nordisk faces headwinds from regulatory uncertainty, competitive efficacy gaps with Eli Lilly and technical downward ...

Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

Walmart will offer in‑store pickup of Eli Lilly’s discounted weight‑loss drug Zepbound, giving self‑pay customers easier, ...

The U.S. stock market is pulling back from its record heights as Wall Street sifts through mixed developments on everything ...